Clinical Trial Update: CiPA Phase 1 ECG Biomarker Validation Study [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating CiPA ECG biomarker in relation to drug-induced QT prolongation with pharmacokinetics data; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Drug-induced Qt Prolongation

Snippet

Sponsor: Food and Drug Administration (FDA) | Conditions: Drug-induced QT Prolongation, Pharmacokinetics | Phase 1 | Status: COMPLETED | Results posted: 2020-01-18